Overview

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

Status:
RECRUITING
Trial end date:
2029-07-09
Target enrollment:
Participant gender:
Summary
This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.
Phase:
PHASE2
Details
Lead Sponsor:
Mao Jianhua